Dominika Suchonova2023-03-27T13:59:35+00:0014-03-2023|News|
On the occasion of the Brain Awareness Week, the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) launch the RETHINKING Alzheimer's disease White Paper, calling for change in the detection and diagnosis of Alzheimer's disease. About Alzheimer's disease Alzheimer’s disease (AD), the most common form of [...]
Dominika Suchonova2023-02-10T14:14:55+00:0024-01-2023|News|
Every three seconds someone develops dementia and for most of these individuals this will be as a result of Alzheimer’s disease, the leading cause. Alzheimer's is a relentless neurodegenerative condition which robs people of their memories, their independence, their relationships, and ultimately, their lives. On 24 January 2023, the European Brain Council (EBC), in collaboration [...]
Dominika Suchonova2023-01-10T12:03:16+00:0008-12-2022|News|
Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]
Dominika Suchonova2023-01-10T13:12:36+00:0024-11-2022|News|
The launch event of the RETHINKING Alzheimer's disease White Paper, calling for change in Alzheimer's care, will take place virtually on 24 January 2023 at 12:30 - 14:00. About Alzheimer's disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause [...]
Dominika Suchonova2023-01-11T08:46:20+00:0010-11-2022|
The launch event of the RETHINKING Alzheimer’s disease White Paper, calling for change in Alzheimer’s care, will take place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper is [...]
Dominika Suchonova2023-02-06T12:34:26+00:0026-10-2022|News|
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health needs. It represents between 60% and 70% of the dementia cases. It is still diagnosed too late when the symptoms become evident as the disease progresses. AD is now portrayed as continuum consisting of 3 stages: [...]
Dominika Suchonova2023-02-24T10:57:04+00:0016-09-2022|
Alzheimer’s disease (AD) is a major unmet medical need that requires innovation to be aligned with public health and health systems‘ needs. AD represents between 60 and%70% of the dementia cases. It is still diagnosed too late, when the symptoms become more evident as the disease progresses. AD is now portrayed as a continuum [...]
Dominika Suchonova2021-07-07T11:46:51+00:0005-07-2021|News|
Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur, and the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterized by a decline in memory, thinking, [...]
admin_ebc2019-10-03T10:00:16+00:0003-10-2019|News|
Experts call for coordinated public education and research programmes to avert a brain disease crisis Experts are calling for a public health campaign aimed at promoting a ‘brain-healthy lifestyle’ to reduce the risk of developing neurodegenerative brain diseases, such as Alzheimer’s disease and Parkinson’s disease. The campaign should support existing health promotion work by [...]
admin_ebc2019-04-03T08:12:29+00:0003-04-2019|News|
Alzheimer’s disease (AD) – the most common cause of dementia – is one of the most significant medical and societal challenges of our time. It does not discriminate and affects everyone, across all generations – from the people who develop the condition, to the families that care for them and the taxpayers who fund health [...]